

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 6 August 2014 – On 1 May 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.

Under the programme initiated 1 May 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 4.0 billion in the period from 1 May 2014 to 5 August 2014. The programme is now concluded.

Since the announcement as of 28 July 2014, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	14,527,000		3,546,958,334
28 July 2014	250,000	253.17	63,293,075
29 July 2014	250,000	256.55	64,137,550
30 July 2014	260,000	258.23	67,140,658
31 July 2014	260,000	257.92	67,059,252
1 August 2014	260,000	251.11	65,289,250
4 August 2014	260,000	251.90	65,495,274
5 August 2014	237,000	255.09	60,456,970
Accumulated under the programme	16,304,000		3,999,830,363

With the transactions stated above, Novo Nordisk owns a total of 34,741,014 B shares of DKK 0.20, corresponding to 1.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 5 August 2014, Novo Nordisk has repurchased a total of 31,737,995 B shares equal to a transaction value of DKK 7,704,518,499.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
----------------------	---------------	--

Investors:

Kasper Roseeuw Poulsen	+45 3079 4303	krop@novonordisk.com
------------------------	---------------	--

Jannick Lindegaard Denholt	+45 3079 8519	jlis@novonordisk.com
----------------------------	---------------	--

Daniel Bohsen	+45 3079 6376	dabo@novonordisk.com
---------------	---------------	--

Frank Daniel Mersebach (US)	+1 609 235 8567	fdni@novonordisk.com
-----------------------------	-----------------	--